Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Position Trimmed by Perpetual Ltd

Perpetual Ltd cut its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 58.4% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 3,718 shares of the biopharmaceutical company's stock after selling 5,213 shares during the period. Perpetual Ltd's holdings in Alnylam Pharmaceuticals were worth $1,004,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Brighton Jones LLC acquired a new position in shares of Alnylam Pharmaceuticals in the fourth quarter worth about $243,000. Truist Financial Corp increased its holdings in Alnylam Pharmaceuticals by 136.6% during the 4th quarter. Truist Financial Corp now owns 4,398 shares of the biopharmaceutical company's stock worth $1,035,000 after purchasing an additional 2,539 shares during the last quarter. IFP Advisors Inc increased its holdings in Alnylam Pharmaceuticals by 24.2% during the 4th quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company's stock worth $57,000 after purchasing an additional 47 shares during the last quarter. Amalgamated Bank raised its position in shares of Alnylam Pharmaceuticals by 2.5% in the 4th quarter. Amalgamated Bank now owns 8,484 shares of the biopharmaceutical company's stock valued at $1,996,000 after purchasing an additional 205 shares in the last quarter. Finally, Nwam LLC boosted its stake in shares of Alnylam Pharmaceuticals by 5.8% during the 4th quarter. Nwam LLC now owns 906 shares of the biopharmaceutical company's stock valued at $213,000 after buying an additional 50 shares during the last quarter. Hedge funds and other institutional investors own 92.97% of the company's stock.

Insider Activity

In other news, CEO Yvonne Greenstreet sold 31,640 shares of the company's stock in a transaction on Friday, May 30th. The stock was sold at an average price of $304.39, for a total value of $9,630,899.60. Following the completion of the sale, the chief executive officer owned 48,948 shares in the company, valued at $14,899,281.72. This represents a 39.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Company insiders own 1.20% of the company's stock.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ ALNY traded up $5.93 during midday trading on Wednesday, reaching $327.99. 627,284 shares of the company traded hands, compared to its average volume of 857,727. The company has a market cap of $42.77 billion, a price-to-earnings ratio of -157.06 and a beta of 0.23. The stock has a 50-day moving average price of $289.81 and a 200 day moving average price of $264.42. Alnylam Pharmaceuticals, Inc. has a 52 week low of $205.87 and a 52 week high of $339.59. The company has a debt-to-equity ratio of 8.88, a current ratio of 3.04 and a quick ratio of 2.98.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.07). Alnylam Pharmaceuticals had a negative net margin of 11.49% and a negative return on equity of 510.31%. The company had revenue of $594.19 million during the quarter, compared to the consensus estimate of $584.32 million. During the same quarter last year, the business earned ($0.16) earnings per share. The company's revenue was up 20.2% on a year-over-year basis. Sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on ALNY. Scotiabank lifted their price target on shares of Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the stock a "sector outperform" rating in a research note on Monday, March 31st. Citigroup boosted their target price on shares of Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the stock a "buy" rating in a research report on Friday, March 21st. Royal Bank Of Canada increased their price target on shares of Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the stock an "outperform" rating in a research report on Friday, March 21st. Needham & Company LLC lifted their price target on Alnylam Pharmaceuticals from $320.00 to $377.00 and gave the stock a "buy" rating in a research note on Thursday, June 26th. Finally, William Blair restated an "outperform" rating on shares of Alnylam Pharmaceuticals in a research note on Friday, March 21st. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and twenty have given a buy rating to the stock. According to MarketBeat, Alnylam Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $340.00.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.